康惠制药(603139) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥121,353,198.96, a decrease of 4.72% compared to ¥127,367,068.27 in the same period last year[3] - The net profit attributable to shareholders of the listed company was -¥17,239,346.14, representing a significant decline of 1,686.98% from a profit of ¥1,086,299.01 in the previous year[3] - The net cash flow from operating activities was -¥16,567,774.08, a decrease of 294.43% compared to ¥8,521,044.26 in the same period last year[3] - Basic and diluted earnings per share were both -¥0.17, a decrease of 1,800.00% from ¥0.01 in the previous year[5] - The weighted average return on equity was -1.92%, down from 0.11% in the same period last year[5] - The net profit for the first quarter of 2025 was -27,456,184.89 RMB, compared to -2,482,990.60 RMB in the same period of 2024, indicating a significant decline in profitability[24] - The total revenue from operating activities decreased to 124,403,140.61 RMB in Q1 2025, down from 179,435,753.02 RMB in Q1 2024, representing a decline of approximately 30.6%[29] - The total operating profit for Q1 2025 was -27,289,895.68 RMB, compared to -1,225,055.56 RMB in Q1 2024, reflecting a substantial increase in operating losses[24] - The company’s total comprehensive income attributable to shareholders of the parent company was -17,239,346.14 RMB in Q1 2025, compared to 1,086,299.01 RMB in Q1 2024[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,917,799,690.98, an increase of 1.59% from ¥1,887,841,880.34 at the end of the previous year[5] - The equity attributable to shareholders of the listed company decreased by 2.01% to ¥840,082,845.88 from ¥857,322,192.02 at the end of the previous year[5] - Total liabilities increased to CNY 1,038,351,488.50, up from CNY 980,937,492.97 at the end of 2024[20] - Cash and cash equivalents increased to CNY 104,919,342.55 as of March 31, 2025, up from CNY 97,600,121.36 at the end of 2024[18] - Accounts receivable rose to CNY 220,063,605.23, an increase of 2.8% from CNY 214,405,586.89 at the end of 2024[18] - Inventory decreased to CNY 188,912,668.12, down 3.0% from CNY 195,492,565.52 at the end of 2024[16] - Short-term borrowings increased to CNY 232,091,309.14, up 23.7% from CNY 187,509,578.94 at the end of 2024[18] - Total assets as of March 31, 2025, were CNY 1,917,799,690.98, an increase from CNY 1,887,841,880.34 at the end of 2024[18] Government Support and Costs - The company received government subsidies amounting to ¥1,788,649.10, which are closely related to its normal business operations[6] - The decline in net profit was primarily due to rising costs and expenses[7] - Total operating costs increased to CNY 150,382,034.67 in Q1 2025, up 12.8% from CNY 133,377,175.40 in Q1 2024[22] - Gross profit margin decreased, with operating costs representing 124.0% of operating revenue in Q1 2025 compared to 104.7% in Q1 2024[22] Cash Flow Activities - The net cash flow from operating activities for Q1 2025 was -16,567,774.08 RMB, contrasting with a positive cash flow of 8,521,044.26 RMB in Q1 2024[31] - The company reported a cash inflow from financing activities of 70,428,932.28 RMB in Q1 2025, an increase from 57,835,650.66 RMB in Q1 2024[32] - The cash and cash equivalents at the end of Q1 2025 amounted to 104,918,488.36 RMB, compared to 94,196,181.65 RMB at the end of Q1 2024, showing an increase of approximately 11.5%[33] - The cash outflow from investing activities in Q1 2025 was -6,083,635.93 RMB, down from -10,167,044.79 RMB in Q1 2024, indicating a reduction in investment expenditures[31] Credit and Impairment - The company incurred a credit impairment loss of -57,286.31 RMB during the reporting period[24]